"Dr. George D. Yancopoulos, chief scientific officer of Regeneron, said the crisis had pointed up shortcomings in biodefense. 'Nobody is really prepared,' he said. 'Nobody in the world has rapid response capabilities.'"
- New York Times, January 2015
The primary benefit of microalgae for antibodies is their quick and cheap scale-up. We envision kgs worth of antibody being produced by microalgae in raceway ponds for rapid and inexpensive availability.